25.09.2024
Egnach, September 25, 2024 – From October 2024, the tinniwell will also be available in Turkey. An exclusive distribution agreement for the tinnitus therapy device could now be closed. With an average number of approx. 15% tinnitus affected by the population, there is a market potential of around 13 million patients.
Soon the conclusion of further country licenses is expected.
++ About Resaphene Suisse AG
Resaphene Suisse AG, based in Egnach, Switzerland, is a medical technology company that was founded in 2015 and has been selling a tinnitus therapy device under the name tinniwell since 2016.
++ Contact for questions:
Resaphene Suisse AG
Mrs. Anke Rauterkus (Chief Executive Officer)
Bahnhofplatz 5
9322 Egnach
Switzerland
T. +41 714500668